CURRICULUM VITAE DR. ADINA MAZILU POZITIE VITAE DR. ADINA MAZILU POZITIE ACTUALA: medic primar Endocrinologie din 2014 - prezent medic specialist Diabet zaharat, Nutritie si Boli metabolice din ...

  • Published on
    12-Feb-2018

  • View
    213

  • Download
    1

Embed Size (px)

Transcript

<ul><li><p>CURRICULUM VITAE </p><p>DR. ADINA MAZILU </p><p>POZITIE ACTUALA: </p><p>medic primar Endocrinologie din 2014 - prezent </p><p>medic specialist Diabet zaharat, Nutritie si Boli metabolice din 2013-prezent </p><p>angajata a S.U.U.M.C Dr. Carol Davila Sectia Endocrinologie </p><p>competenta in Ecografia glandelor endocrine si Sexologie </p><p>diploma de Certified Clinical Densitometrist - 2008 </p><p>experienta in DXA-operare si interpretare DXA din 2008 </p><p>responsabil cu Nutritia in cadrul SUUMC Dr. Carol Davila </p><p>responsabil de Management infectii nosocomiale in cadrul Sectiei Endocrinologie a </p><p>SUUMC Dr. Carol Davila </p><p>curs de Prim ajutor medical specializat 2000 si curs de Radioprotectie 2016 </p><p>COMPETENTE PERSONALE: </p><p>LB. ENGLEZA- NIVEL C1 </p><p>LB. FRANCEZA- NIVEL C1 </p><p>PARTICIPARE LA EMISIUNI TELEVIZATE-FRESH REFRESH-REALITATEA </p><p>TV-2016, B1 TV, TVR 1, Kanal D </p><p> STUDII CLINICE MULTICENTRICE - SUBINVESTIGATOR 2003-2009 A long-term study of sibutramine and the role of obesity management in relation to cardiovascular disease in overweight and obses patients (SCOUT), trial de faza III, 2003- 2009.http://clinicaltrials.gov/show/NCT00234832. Sponsor- Abbott, directorul studiului Cheryl Renz, MD 2005-2009 ROADMAP, (Randomized Olmesartan an Diabetes microalbuminuria Prevention Study)trial de faza III.http://clncaltrals.gov/show/NCT00185159. Sponsor Sankyo Pharma Gmbh 2006-2009 PLANET 1 (D3569C00007)- Randomised, Double-blind, 52-wk, Parallel-grp, Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Diabetic Patients With Moderate Proteinuria,trial faza II, http://clinicaltrials.gov/ct2/show/NCT00296374, Sponsor Astra Zeneca 2000-2003 Protocol 306A1-300-EUA Multicenter, Double Blind, Randomized, Placebo and Raloxifene Controlled Study to Assess Safety and Efficacy of TSE-424 (Bazedoxifene Acetate) in the Prevention of Postmenopausal Osteoporosis, trial de faza III,http://clinicaltrials.gov/show/NCT00481169 , Wyeth Research 2007-2009 Protocol 3047K5-319-WWA Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once-Daily Dose of Tigecycline Versus Ertapenem for the Treatment of Foot Infections in Subjects With Diabetes.http://clncaltrals.gov/ct2/show/studv/NCT00366249. Wyeth Research 2007-2010 International, Multi-center Post Authorization Surveillance Study on the Use of Nebido to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice (IPASS Nebido), trial de fazaIII. http://clncaltrals.gov/ct2/show/NCT00410306. Sponsor Bayer 2003- 2013 Protocol 3068A1-301-WW: Fracture Incidence Reduction And Safety Of TSE-424 (Bazedoxifene Acetate) Compared To Placebo And Raloxifene In Osteoporotic Postmenopausal Women, http://clinicaltrials.gov/ct2/show/NCT00205777 , trial de faza III, Wyeth Research 2012-2015,A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome (ELIXA)- studiuclinic multinational, multicentric de faza III, sindroame coronare acute, 2010-2015, http://clinicaltrials.gov/show/NCT01147250; sponsor Sanofi-Aventis </p></li><li><p>03.2013-07.2013 A Phase IIIB study to evaluate the potential of Aleglitazar to reduce cardiovascular risk in patients with stable cardiovascular disease and glucose abnormalities;http://clinicaltrials.gov/ct2/show/NCT01715818 ; trial de faza IIIB; Sponsor Hoffman-LaRoche 2012-2014 A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Add-On Therapy With Saxagliptin and Dapagliflozin Added to Metformin Compared to Add-On Therapy With Saxagliptin in Combination With Metformin or Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone; MB102-129 Study; trial de faza III; https://clinicaltrials.gov/ct2/show/NCT01606007; Sponsor Bristol-Myers Squibb 2012-prezent A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Triple Therapy With Saxagliptin Added to Dapagliflozin in Combination With Metformin Compared to Therapy With Placebo Added to Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin and Dapagliflozin; stdiu de faza III multicentric, multinational:http://clinicaltrials.gov/ct2/show/studv/NCT01619059 ; Sponsor Bristo-Myers Squibb Company 2012-prezent A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Therapy With Dapagliflozin Added to Saxagliptin in Combination With Metformin Compared to Therapy With Placebo Added to Saxagliptin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin and Saxagliptin; studiu clinic de faza III multicentric, multinational;http://clinicaltrials.gov/show/NCT01646320 ; Sponsor Bristol-Myers Squibb Company 03.2013-07.2013 A Phase IIIB study to evaluate the potential of Aleglitazar to reduce cardiovascular risk in patients with stable cardiovascular disease and glucose abnormalities;http://clinicaltrials.gov/ct2/show/NCT01715818 ; trial de faza IIIB; Sponsor HoffmanLaRoche 2013-prezent Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of PF 04950615, In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects; studiu clinic de faza III;http://clinicaltrials.gov/show/NCT01975389 ; Sponsor Pfizer 2014-2016 A Randomised, Double Blind, Placebo Controlled, Parallel Group, Dose Ranging Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes; http://clinicaltrials.gov/ct2/show/NCT02053272 ; Sponsor GW Pharmaceuticals 2013-prezent A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events;http://clinicaltrials.gov/ct2/show/NCT01968954 ; sponsor Pfizer 2014- prezent A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallelgroup Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to LixisenatideAlone on Top of Metformin in Patients With Type 2 Diabetes Mellitus T2DM; http://clinicaltrials.gov/ct2/show/NCT02058147 ; sponsor Sanofi Aventis 2014-prezent A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy, http://www.clinicaltrials.gov/ct2/show/NCT02065791 ; sponsor Janssen research and Developpment, LLC 2015-prezent A multicenter, randomized, double-blind, placebo-controlled, parallel group, phase 3 trial to evaluate the safety and efficacy of once weekly Exenatide </p></li><li><p>therapy added to titrated Basal Insulin Glargine compared to placebo added to titrated Basal Insulin Glargine in patients with type 2 diabetes who have inadequate glycemic control on Basal Insulin Glargine with or without Metformin; https://clinicaltrials.gov/ct2/show/NCT02229383; sponsor Astra Zeneca 2015-prezent A 28-week, Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study With a 24-week Extension Phase Followed by a 52-week Extension Phase to Evaluate the Efficacy and Safety of Simultaneous Administration of Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg Compared to Exenatide Once Weekly 2 mg Alone and Dapagliflozin Once Daily 10 mg Alone in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin; https://clinicaltrials.gov/ct2/show/NCT02229396 ; sponsor Astra Zeneca CURSURI DE PERFECTIONARE 25-28.10 .2008 Cursurile Postuniversitare ETA (European Thyroid Association),Poiana Brasov, Al XV lea Congres National de Endocrinologie,Asociatia Romana de Endoccrinologie, European Thyroid Association 06.02.2002 GCP Training Complinace, Bucharest, Romania Cursuri de 12 saptamani pentru Competenta de Sexologie Curs de radioprotectie Nivel 2 PREZENTARI LA MANIFESTARI STIINTIFICE INTERNE: 26.09.2013 Simpozion Terapii inovatoare in osteoporoza- primii doi ani de experienta si concluzii; Congresul Nationala de Endocrinologie cu Participare Internationala, ed XXI, 25-26.09.2013 2006-2009 Reductil presentations- Abbott Prezentari pentru compania Abbott, Amgen, MSD LUCRARI STIINTIFICE CONGRESE: 1. Micro- si macroprolactinoamele sunt dou boli distincte? Diagnostic - Congresul European de Endocrinologie - Torino, Italia, 9-13 iunie 2001 2. Consequences of belated treatment in primary mixedema- AE Ranetti, N Diaconu, C Spiroiu, C Dumitrache, S Blaj, V Mihalache, M Flueras, A Onofrei;poster presentation, 5th European Congress of Endocrinology, 09-13.06.2001, Turin Italy, rezumat publicat in volumul de rezumate al congresului 3. Efectele Sibutiraminei asupra profilului lipidic; Dr A.E. Ranetii, Dr. Adina-Onofrei-Mazilu, Congresul National Obezitatea si bolile asociate, Cluj 2001 4. Hiperparatiroidismul secundar la femeile n postmenopauz - incident, aspecte clinice, implicatii terapeutice; Dr. A. Ranetti, dr. N.Diaconu, Dr. C.Spiroiu, dr. Ana-Maria Mihai, Dr. Adina Mazilu - CongresulNational de Endocrinologie - Craiova, 5-7iunie2003 5. Tiroidita cronic autoimun asociat cu alte boli autoimune; Dr. A. Ranetti, dr. N.Diaconu, Dr. C.Spiroiu, dr. Ana-Maria Mihai, Dr. Adina Mazilu - Congresul National de Endocrinologie - Craiova, 5-7 iunie 2003 6. Consideratii terapuetice privind disfunctia erectila la pacientii diabetici- AE Ranetti, C Spiroiu, AM Mihai, N diaconu, A Mazilu; Al 29lea congres national de diabet, nutritie si boli metabolice cu particpare internationala, 14-17 mai 2003, Craiova, rezumat publicat in Acta diabetologica Romana , vol XXIX 2003 7. Aspecte etiopatogenice si clinico-evolutive ale unor forme secundare de diabet zaharat; dr. A.E. Ranetti, dr. C.Spiroiu,dr. A.Mihai, dr. A.Mazilu; Al 29lea congres national de diabet, nutritie si boli metabolice cu particpare internationala, 14-17 mai 2003, Craiova, rezumat publicat in Acta diabetologica Romana , vol XXIX 2003 8. Endocrinological features of atrial fibrillation; dr. A.E. Ranetti, dr.C.Spiroiu,dr.A.Mihai,dr.A.Mazilu; 8th Congress of Balkan Military Medical Committee, 2124 sept 2003, Cluj Napoca, Romania, Rezumat publicat in volumul de rezumate al congresului </p></li><li><p>9. Clinical and pathological aspects of some secondary forms of diabetes mellitus; dr. A.E. Ranetti, dr. C.Spiroiu, dr. A.Mihai, dr.A.Mazilu; 8th Congress of Balkan Military Medical Committee, 21-24 sept 2003, Cluj Napoca, Romania, Rezumat publicat in volumul de rezumate al congresului 10. Feocromocitomul malign bilateral - prezentare atipic - ENEA -Sorrento, Italia, 24-27 aprilie 2004 11. Tiroidita subacut si bicitopenia dup terapia cu interferon 2-a administrat n hepatite - ENEA - Sorrento, Italia, 24-27 aprilie 2004 12. Poliglandular autoimmune syndrome associated with meningioma; dr. A.E. Ranetti, dr. C.Spiroiu, A.Mihai, A.Mazilu;Congresul Balcanic de Medicin Militar, Istanbul, iunie 2004 13. Management of thyroid cancer in children - 5 years experience; dr. A.E. Ranetti, dr. C.Spiroiu, dr. A.Mihai, dr. A.Mazilu;Congresul Balcanic de Medicin Militar, Antalya, iunie 2004 14. Particularitti evolutive n carcinomul papilar tiroidian; dr.A.Mazilu, dr.A.E.Ranetti,R.Mititelu,GMarinescu,Prof.dr.Codorean;Congresul National de Endocrinologie,Timisoara, 2004 15. Modificri psihice la o serie de pacieni cu boal Graves-Basedow -Congresul National de Neuroendocrinologie-Poiana Brasov, 3-6 iunie 2004 16. Sindromul depresiv n hiperprolactinemii - Congresul National de Neuroendocrinologie - Poiana Brasov, 3-6 iunie 2004 17. Dificulti de diagnostic n insulinoame - Congresul National de Neuroendocrinologie - Poiana Brasov, 3-6 iunie 2004 18. Pollyglandular autoimmune syndrome associated with meningioma.Adina Mazilu,., Ana- Maria Mihai, Cristina Spiroiu., Lt-Col. A.E.Ranetti, 9th Congress of Balkan Military Medical Committee,21-24 June 2004, Antalya, TURKEY Abstract published in Balkan Military Medical Review 19. The efficacy of levothyroxine therapy in the nontoxic multinodular goiter,A.E.Ranetti C Spiroiu , Am. Mihai , A. Mazilu , C. Ranetti Pharmacist, C.Stefan. D Mihai . 9th Congress ofBalkan Military Medical Committee,21-24 June 2004, Antalya, TURKEY 20. Follow-up of fibrocystic mastosis In postmenopausal women; Adina Mazilu, Ana-Maria Mihai, Cristina Spiroiu.,Lt-Col. A.E.Ranetti, 9th Congress ofBalkan Military Medical Committee,21- 24 June 2004, Antalya, TURKEY, 21. Prevalence of the metabolic syndrome in overweight adults. Adina Mazilu, , Ana-Maria Mihai, Cristina Spiroiu, Lt-Col. A.E.Ranetti, M. Costin , 9th Congress of Balkan Military Medical Committee,21-24 June 2004, Antalya, TURKEY Abstract published in Balkan Military Medical Review 22. A rare form of secondary osteoporosis - osteogenesis imperfecta - Case Report - C. Spiroiu, A.E.Ranetti, N. Diaconu, A. Popescu, A. Mazilu, A.M. Mihai, Cpt. C. Ranetti, Pharm. , 9th Congress ofBalkan Military Medical Committee,21-24 June 2004, Antalya, TURKEY; 23. Ulceration in diabetic foot - Dr. N. Diaconu. Dr. A.E.Ranetti. Dr. C. Spiroiu, Dr. Ana-Maria Mihai, Pharm. Cristina Ranetti, Dr. Adina Mazilu, 9th Congress of Balkan Military Medical Committee,21-24 June 2004, Antalya, TURKEY Abstract published in Balkan Military Medical Review 24. Consecinte ale patologiei endocrine in stomatologie, Congresul International de Stomatologie, 8-11 martie 2005, Bucuresti, Romania; A.E. Ranetti, C.Spiroiu, A. Mazilu,A.M. Mihai 25. Sibutiramine efficiency in metabolic control of obese diabetic patients- A Mazilu, A Mihai, C Spiroiu, AE Ranetti, oral presentation, 14th European Congress on Obesity 1-4.06.2005 26. Pregnancies in women with premature ovarian failure. A.E.Ranetti; A.M. Mihai; C.Spiroiu; A.Mazilu - The 13th Balkan Congress of Endocrinology, 19-22 October 2005, Bucharest, Romania; Abstract published in Balkan Military Medical Review </p></li><li><p>27. Papillary thyroid carcinoma with invasion in the medullary canal T1 - T2 - A.E.Ranetti; A.M. Mihai; C.Spiroiu; A.Mazilu- The13th Balkan Congress of Endocrinology, 19-22 October 2005, Bucharest, Romania; 28. The efficacy of levothyrooxine therapy in the nontoxic multinodular goiter- AM Mihai, AE Ranetti, C Spiroiu, A Mazilu,C Ranetti, poster presentation, 8th european Congress of Endcorinology incorporating the British Endocrine Societies, abstract published in 'Endocrine Abstracts, ISSN 1470-3947 (print), ISSN 1479-6848 (on-line), volume 11, april 2006, 1-5 april 2006, Glasgow, UK 29. Management of thyroid cancer in c...</p></li></ul>